McKesson Stock Is Down 24% From Its 52-Week High: Analysts See 46% Upside to $1101 Target
McKesson (MCK) reported strong Q4 FY2026 earnings, surpassing analyst estimates, with full-year EPS up 49% and revenue climbing 12%. Despite these positive results and strategic moves like selling a minority stake in its Medical-Surgical unit, the stock is trading 24% below its 52-week high. Analysts project a potential 46% upside to $1,101 per share by March 2029, driven by dominant pharmaceutical distribution, a growing oncology segment, and consistent EPS expansion.
https://www.tikr.com/blog/mckesson-stock-is-down-24-from-its-52-week-high-analysts-see-46-upside-to-1101-target